Skip to main content
Premium Trial:

Request an Annual Quote

Ligon Discovery Nets $1M Investment

NEW YORK (GenomeWeb News) – Ligon Discovery, a protein microarray developer based in Cambridge, Mass., has reeled in $1 million in financing from IncTank Ventures, Ligon Discovery Co-founder Patrick Kleyn confirmed today.

The firm plans to use the venture funding to screen more than 100 proteins that could be used for drugs.

Ligon's small-molecule microarrays (SMMs) technology platform was developed by and licensed from Harvard University and Broad Institute.

SMMs use surface chemistry technology to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function, according to the firm's website.

The technology enables researchers to screen entire protein families, molecular pathways, and genome-wide targets in parallel to identify small molecules with optimal characteristics for drug development.

The company also confirmed that IncTank General Partner Christian Bailey has joined Ligon's board of directors.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.